Reports Outline Hepatitis Study Findings from Sichuan University (Evaluation of the implementation effect of hepatitis C medical insurance reimbursement policy in China: A RWS based on medical institutions): Liver Diseases and Conditions – Hepatitis

2023 JAN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- New study results on hepatitis have been published. According to news reporting originating from Chengdu, People’s Republic of China, by NewsRx correspondents, research stated, “ObjectivesTo evaluate the implementation effect of hepatitis C medical insurance reimbursement policy in China from the view of medical institutions.”

The news correspondents obtained a quote from the research from Sichuan University: “MethodsThe electronic medical record of a top tertiary hospital in Chengdu from January 2014 to December 2020 were extracted, and the interrupted time series model was used to analyze the changes in diagnosis and treatment behavior and disease burden of hepatitis C patients after the implementation of HCV insurance reimbursement policy. ResultsIn terms of diagnosis and treatment, the number of visits (b2 = 19.290, P < 0.001) and treatments (b2 = 14.291, P < 0.01) increased instantaneously after the implementation of the outpatient reimbursement policy in Chengdu in 2018, and there was no significant change after the implementation of the single line payment policy for oral direct antiviral (DAA) drugs in 2019 (P > 0.05); in terms of medical expenses, the total treatment cost (b2 = 21439.3, P < 0.001), out-of-pocket expenses (b2 = 6109.44, P < 0.001) and drug expenses (b2 = 21889.8, P < 0.001) of hepatitis C patients have been significantly reduced after the implementation of the single-line payment policy.”

According to the news reporters, the research concluded: “ConclusionHepatitis C medical insurance reimbursement policy can promote hepatitis C patients to actively seek medical treatment, promote the widespread use of DAA scheme, reduce the burden of patients, and improve the treatment efficiency of hepatitis C.”

For more information on this research see: Evaluation of the implementation effect of hepatitis C medical insurance reimbursement policy in China: A RWS based on medical institutions. Frontiers in Public Health, 2023,10. (Frontiers in Public Health - http://journal.frontiersin.org/journal/public-health). The publisher for Frontiers in Public Health is Frontiers Media S.A.

A free version of this journal article is available at https://doi.org/10.3389/fpubh.2022.1072493.

Our news editors report that more information may be obtained by contacting Yiyao Liu, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China. Additional authors for this research include Liangwen Gou, Zhaoting Guo, Zhiang Wu, Qin He, Haihuan Feng, Ming Hu. Our reports deliver fact-based news of research and discoveries from around the world.